CellaVision — Earnings Release 2013

Jan 15, 2014

This in nformation w was released f for public disc closure on Jan nuary 15, 201 14 at 8.25 am CET.

Cella aVision rev vises outlo ook for the e full year: Sales grow wth in 201 13

CellaV comp growt year r Vision annou parison with t th for the ful report 2013. nces that sal the correspon l year 2013, i es for the fou nding quarte n contrast to urth quarter o r in 2012. Thi o what was co of 2013 has i is means that ommunicated ncreased sign t the compan d in the comp nificantly in ny shows sale pany's half‐ es

The p per ce cent i impro reliminary fig ent in compar n comparison oved profitab gures for the y rison with 20 n to last year. ility. year 2013 sho 12. Sales in th . The strong s ow that Cella he fourth qua sales growth c aVision's reve arter of 2013 combined wit nue will incre will increase th cost contro ease by 5‐7 by 28‐30 per ol generate

In the yet se placin distrib Tradit e second half een a confide ng first quarte buted over th tionally, sales of 2013 Cella nt trend impr er orders earl he year, depe s in the fourth aVision saw a rovement. Th ier than expe nding on the h quarter is st rise in the US he sales increa ected. CellaVi distributors' trong. S and Europe ase is partly e sion's inflow sales and inv an markets b explained by c of orders is u ventory levels but have not customers unevenly s.

As pre 2014 eviously anno with complet ounced, CellaV te figures on Vision will pu financial deve ublish its Year elopment. r‐end bulletin n 2013 on Feb bruary 13,

For m more informat tion, please c contact:

Yvonn Tel: + ne Mårtensso 46708337782 on, CEO, Cella 2 | Email: yvo aVision AB onne.martens sson@cellavis sion.com

Abou t CellaVision

CellaV leadin analys exam work, hospit autom growt in Lun the N Vision is an in ng systems fo ses often con ple of infectio , and secure a tals. The com mated micros th target of at nd and the co asdaq OMX S novative, glo or routine ana nstitute impor ons and serio and support e mpany has lea copy. In 2012 t least 15 % p ompany has su Stockholm, Sm obal medical t alysis of blood rtant referenc ous cancers. C effective work ding‐edge ex 2 sales were S per year over ubsidiaries in mall Cap list. R technology co d and other b ce data for fa CellaVision's p kflows and sk pertise in ima SEK 170 millio an economic the USA, Can Read more at ompany that d ody fluids in ast and correc products ratio kills developm age analysis, on and sales c c cycle. CellaV nada and Japa t www.cellavi develops and health care s ct diagnosis o onalize manu ment within a artificial inte continue to in Vision's regist an. The share ision.com. d sells its own ervices. The of illnesses, fo al laboratory nd between lligence and ncrease, with ered office is e is listed on rnor a s